RecruitingPhase 2NCT05470504
Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance
Studying Acquired partial lipodystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Principal Investigator
- Rebecca J Brown, M.D.National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Intervention
- Pegvisomant(drug)
- Enrollment
- 25 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2023 – 2028
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05470504 on ClinicalTrials.govOther trials for Acquired partial lipodystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07516496Metabolic Phenotyping in vEDSCambridge University Hospitals NHS Foundation Trust
- RECRUITINGPHASE4NCT06484868Open-label Study to Evaluate Metreleptin in Patients With Partial LipodystrophyAmryt Pharma
- RECRUITINGNCT05996536Feasibility of Adipose Tissue Triglyceride (TG) Labelling in Familial Partial Lipodystrophy (FPLD)National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- ACTIVE NOT RECRUITINGPHASE3NCT05164341Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PLAmryt Pharma
- RECRUITINGNANCT03900286Low Energy Diet and Familial Partial LipodystrophyCambridge University Hospitals NHS Foundation Trust
- ACTIVE NOT RECRUITINGPHASE2NCT02262806Compassionate Use of Metreleptin in Previously Treated People With Partial LipodystrophyNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)